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Residue variabilityEscherichia coli EmrE is a small multidrug resistance protein encompassing four transmembrane
(TM) sequences that oligomerizes to confer resistance to antimicrobials. Here we examined the
effects on in vivo protein accumulation and ethidium resistance activity of single residue substitu-
tions at conserved and variable positions in EmrE transmembrane segment 2 (TM2). We found that
activity was reduced when conserved residues localized to one TM2 surface were replaced. Our ﬁnd-
ings suggest that conserved TM2 positions tolerate greater residue diversity than conserved sites in
other EmrE TM sequences, potentially reﬂecting a source of substrate polyspeciﬁcity.
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Widespread use of antimicrobials has resulted in the emergence
of nosocomial pathogens such as methicillin resistant Staphylococ-
cus aureus (MRSA, [1]), an organism that causesmore deaths among
U.S. hospital patients than HIV/AIDS and tuberculosis combined [2].
Persistence of MRSA strains is linked to multidrug efﬂux transport-
ers of the small multidrug resistance (SMR) family [3,4]. Indeed, the
ﬁrst SMR identiﬁed, Smr/QacC, was isolated from clinical S. aureus
resistant to cationic disinfectants and antiseptics (termed biocides)
[5]. Half of sequenced bacterial chromosomes, and numerous plas-
mids and transposons, contain SMR protein genes [6,7] from among
three subclasses [suppressor of groEL mutation (SUG); paired SMR
(PSMR); and small multidrug protein (SMP)]. SMPs associate withbacteria that are pathogenic and/or sources of nosocomial infection
[3–5,8–11]; theirmaintenancewithin suchmicroorganisms reﬂects
frequent exposure to biocidal quaternary ammonium compounds
(QACs) and other naturally-occurring or man-made toxicants [7].
The Escherichia coli SMP EmrE is the functional and structural
paradigm of SMRs. EmrE is a 110-residue antiporter of the inner
membrane that extrudes substrates in exchange for two protons
[12]. EmrE substrates include natural and man-made QACs (beta-
ine, choline [13] and tetraphenylphosphonium (TPP) [14]), herbi-
cides (methyl viologen (MV) [15]), dyes (ethidium (Et) [16,17]),
clinical biocides (benzalkonium, acriﬂavine (Ac) [18]), and amino-
glycoside antibiotics (streptomycin, tobramycin [19]). The minimal
functional unit of EmrE is a homodimer [20], although higher-
order oligomers may exist [21–23]. Structural models at sub-
atomic resolution [24–28] of substrate-bound and apo-forms of
the antiparallel dimer are similar [29]: TMs 1–3 of each monomer
form a substrate-binding pocket, and the two TM4 helices form a
dimerization arm. The plasticity and dynamics of apo-EmrE permit
adaptation to substrates via re-arrangements among TMs 1–3
[28,30,31]; TPP binding rigidiﬁes EmrE and changes packing of
TM1, tilting of TM2, and alters backbone conﬁgurations of TM3
and the adjacent loop connecting it to TM4 [30–32]. TM4–TM4
contacts are less variable than those among TMs 1–3, consistent
with the essential role of this helix in dimerization [33–35].
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protein contacts mediating self-assembly and/or substrate translo-
cation have yet to be precisely deﬁned. Lipid-exposed and protein-
facing side chains in the TPP-bound, antiparallel EmrE dimer,
delineated using an atomistic model generated from the X-ray
structure, matched in vivo activity assessments [36]. For example,
Glu14 in TM1 and Gly90/Gly97 in TM4 were found to be protein-
facing and required for Et resistance activity [36], consistent with
conservation of these residues among all SMR proteins [6], and
their respective role(s) in coupling ﬂux of protons and substrates
at TM1 [37], or stabilizing TM4–TM4 dimerization [33–35].
Trp substitutions at protein-facing EmrE TM2 sites (Tyr40, Ser43,
Phe44, Leu47, and Ala48; [36]) also reduced or eliminated Et resis-
tance activity, reinforcing previously-identiﬁed role(s) in activity
and/or folding of select TM2 residues [30,36,38–40]. Tyr40, for
example, is important, although not fully essential, for catalyzing
transport [40], Cys41 forms part of the substrate pathway [38],
and Trp45 may aid EmrE insertion into the cytoplasmic membrane
[41]. TM2 thus participates in activity and folding of SMR proteins.
Here we sought to determine the sensitivity of in vivo EmrE protein
accumulation and Et resistance activity to TM2 residue replace-
ments. Using an alignment of 108 SMPs [7], we classiﬁed TM2 resi-
dues as highly-conserved, semi-conserved, semi-variable, and
variable. By replacing residues at various conservation levels in
site-directed mutagenesis experiments, we found that in vivo EmrE
protein accumulation levels did not universally correlate with resi-
due conservation. However, replacement of each highly-conserved
TM2 residue essentially eliminated in vivo resistance to Et. Our
results show that key functional residues arewithin themost highly
conserved quartile of TM2 positions.Table 1
Descriptive statistics of whole-protein and TM2 sequence variability in aligned SMPs.
Statistic Shannon entropy (H)a
EmrE TM2
Minimum 0.152 0.750
25th Percentile 1.38 1.75
Median 1.94 2.10
75th Percentile 2.56 2.55
Maximum 3.42 2.72
a H values range from 0 (one residue present at a given alignment position) to
4.39 (all 20 residues equally represented, including gaps). Lower H values thus
correspond to higher residue conservation and vice versa. H values among all
positions in the multiple sequence alignment of SMPs that encompass the complete
EmrE protein (residues 1–110), and those corresponding to EmrE TM2 (residues 34–
52), were normally distributed (N = 110 and N = 19, respectively, P > 0.10 in both
cases). Quartile values (25th percentile, median, and 75th percentile) were used to
deﬁne conservation levels (Section 2). Note that H values of eleven alignment
positions were lower than the TM2 minimum (Supplementary ﬁle 1), correspond-
ing to EmrE residues in TM1 (Tyr7 and Glu14), TM3 (Tyr60, Ala61, Trp63, Gly65, and
Gly67), TM4 (Gly90), and in loops (Gly27 and Pro55).2. Materials and methods
2.1. Reagents
The EmrE-Myc/His plasmid [37] was a kind gift from Prof. Shi-
mon Schuldiner, Hebrew University of Jerusalem. E. coli BL21(DE3)
cells and anti-His (C-term)-HRP conjugate antibodies were from
New England Biolabs. Ampicillin was purchased from BioShop.
ECL Plus reagents were purchased from GE Healthcare. GelCode
Blue protein stain and BCA reagents were from Thermo Fisher Sci-
entiﬁc. Amido Black total protein stain and ethidium bromide
(EtBr) solution were from Sigma Aldrich. All SDS–PAGE gels and
molecular weight standards were purchased from Life
Technologies.
2.2. Bioinformatics
The amino acid sequence of EmrE was aligned with 107 other
sequences previously-identiﬁed as SMP [7] using the Clustal O
Web server (v. 1.2.1). Care was taken to exclude sequences of SUGs,
and of PSMRs previously identiﬁed to segregate with SMPs (e.g.
EbrA/EbrB, YvaE/YvaD, and YdgE/YdgF [7]). The resulting multiple
sequence alignment (Supplementary ﬁle 1) was submitted to the
Protein Variability Server (http://imed.med.ucm.es/PVS/, [42]), and
default parameters used to determine the value of Shannon entropy
(H) at eachalignmentposition. Shannonentropy is a sensitivemeans
to estimate the diversity of a multiple sequence alignment
(reviewed in [42]), where values of H at a given position range from
0 (one residue present at a given alignment position) to 4.39 (all 20
residues equally represented, including gaps). Lower H values thus
correspond to higher residue conservation and vice versa.
Cut-offs that deﬁne conserved vs. variable sequence positions
have not been unequivocally deﬁned, although it has been sug-
gested based on analyses of immunoglobulins that positions withH 6 2.0 or H 6 1.0 should be considered semi-conserved or
highly-conserved, respectively [43]. Here, the minimum, 25th per-
centile, median, 75th percentile, and maximum of the group of H
values among all alignment positions encompassing EmrE, and
among those corresponding to EmrE TM2 (Table 1) were calculated
and used to deﬁne conservation levels as follows: highly-
conserved, H 6 25th percentile; semi-conserved, 25th percen-
tile < H 6median; semi-variable, median < H 6 75th percentile;
and variable, H > 75th percentile. EmrE TM sequence start and
end sites followed [39]: TM1, residues 4–21; TM2, residues
34–52; TM3, residues 57–81; TM4, residues 85–105.
2.3. Mutagenesis
The QuikChange Site-Directed Mutagenesis Kit (Stratagene) was
used to construct EmrE point mutants in the EmrE-Myc/His
plasmid, and each mutant was veriﬁed by DNA sequencing at
The Centre for Applied Genomics at the Hospital for Sick Children.
2.4. Ethidium growth assay
Growth of E. coli expressing WT and mutant EmrE proteins in
the presence of Et was assayed on 96-well microplates. E. coli
BL21(DE3) cells were transformed with EmrE-Myc/His plasmid
carrying wild-type (WT) EmrE, EmrE TM2 point mutants, or with
pUC19 (negative control). Isolated colonies of fresh transformants
were grown overnight in 5 mL LB containing 100 lg/mL ampicillin
at 37 C. Each overnight culture was standardized by dilution to an
OD600 = 0.5 in LB and then serially diluted from 101 to 107. An
equal volume of each serial dilution was added to plate wells
and mixed with an equal volume of LB to ﬁnal concentrations of
100 lg/mL ampicillin and 100 lg/mL EtBr. Each growth assay plate
contained at least one serial dilution of WT and of negative control.
Plates were covered with air-permeable rayon plate seals and incu-
bated at 37 C for 20 h, after which cell growth density in each well
was measured by OD600, using uninoculated medium as a refer-
ence. Here, Et resistance is conferred by leaky T7 RNA polymer-
ase-mediated expression of EmrE from the EmrE-Myc/His
plasmid rather than by induced overexpression, thereby avoiding
toxic levels of EmrE [44].
Plots of OD600 at 20 h vs. dilution factor were generated for
WT, mutants, and negative control, and the area under each
growth-dilution curve (AUC) determined. Growth relative to WT
was calculated as:
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Western blots were used to determine total EmrE protein accu-
mulation levels. Samples of cells from the same overnight cultures
used in the growth assay were resuspended in ice-cold PBS con-
taining 0.1 mg/mL lysozyme and protease cocktail inhibitor
(Sigma) and lysed by 3 freeze–thaw cycles. DNAse I (New Eng-
land Biolabs), an equal volume of 1 M MgSO4, and SDS to a ﬁnal
concentration of 2% (w/v) were added to lysates, and total protein
quantitated with the Micro BCA Assay. Five micrograms of total
protein was electrophoresed in MES buffer under reducing condi-
tions in a 1.0 mm thick 4–12% BisTris NuPAGE mini gel according
to the manufacturer’s directions. Proteins were transferred to
0.2 lm nitrocellulose membrane (BioRad) overnight at 4 C in
Towbin’s buffer containing 0.03% (w/v) SDS. Blots were probed
with anti-His (C-term)-HRP conjugate antibodies, exposed to ECL
Plus reagent for 2 min, and signals digitally captured and quanti-
ﬁed using a Li-Cor Odyssey Fc imaging system and manufacturer-
supplied ImageStudio software. Blots were then stained with
Amido Black and the total transferred protein quantiﬁed using
densitometry [45]. Note that these procedures control not only
for equivalency of total protein loaded onto SDS–PAGE, but also
for total protein transferred from the SDS–PAGE gel to nitrocellu-
lose for blot visualization. This additional control was undertaken
to ensure that the total protein accumulation of WT and mutant
EmrE were quantitated as accurately as possible. Thus, protein
accumulation levels of WT and mutant EmrE proteins were deter-
mined as the ratio of Western blot signal intensity to total trans-
ferred protein. Accumulation of each EmrE variant relative to WT
was then calculated as:
Relative protein accumulation
¼Protein accumulation levelmutant=Protein accumulation levelWT
Growth in the presence of Et was then normalized for protein
accumulation:
Relative normalized growth
¼ Relative growth=Relative protein accumulation
Mean values of protein accumulation and relative normalized
growth measurements of each TM2 mutant were used to classify
each into one of three groups relative to WT EmrE, as follows:
low, 625% of mean WT value; moderate, >25% but 675% of WT;
as WT, 75% WT.
2.5. Data analysis
Curve ﬁtting, area calculations, and statistical analyses were
performed with GraphPad Prism 5.0.1. Comparisons of protein
accumulation and growth for individual mutants were performed
by 1-way ANOVA followed by comparison to WT with Dunnett’s
Multiple Comparison Test. Comparisons of accumulation and
growth among groups of mutants at highly-conserved, semi-con-
served, and semi-variable sites were performed by 1-way ANOVA
followed by Tukey’s Multiple Comparison Test. All datasets were
tested for normality prior to analysis. A level of P < 0.05 was used
to denote statistical signiﬁcance.3. Results
3.1. Sequence conservation and variability in TM2 denotes sites for
single residue substitutions
TM2 residues that are required or dispensable for assembly
and/or transport will be conserved or variable among SMPs,respectively. To identify these, the residue diversity of a multiple
sequence alignment of 108 SMP amino acid sequences – including
SMPs from a-, b-, c-, d-proteobacteria, halobacteria, chlorobia, and
plasmids/integrons [7] – was estimated by calculating the Shannon
entropy (H) at each alignment position. Values of H range from 0
(one residue present at a given alignment position) to 4.39 (all
20 residues equally represented, including gaps); thus, lower H val-
ues correspond to higher residue conservation and vice versa. Dis-
tributions of H values among alignment positions corresponding to
the complete EmrE sequence, and to TM2, were subsequently com-
pared (Table 1). We observed that minimum and 1st quartile H val-
ues of the complete EmrE sequence were lower than those of TM2
(Table 1). For example, the most-conserved EmrE position had an H
value <25% that of the most-conserved in TM2 (Gly97 and Leu47;
H = 0.152 and H = 0.750, respectively). Further, ten other alignment
positions – in TMs 1, 3, 4 and two connecting loops – were also
more conserved than the TM2 minimum (Table 1). TM2 thus
appeared to accommodate more residue diversity than other SMP
sites. Our speciﬁc interest in delineating conserved sites within
TM2 accordingly led to use of TM2-speciﬁc H-value quartiles
(Table 1) for classiﬁcation of EmrE TM2 residues as highly-con-
served, semi-conserved, semi-variable, or variable (H 6 1.75,
1.75 < H 6 2.10, 2.10 < H 6 2.55, or H > 2.55, respectively; Fig. 1a
and Table S1).
Consistent with prior observations of helical periodicity among
conserved SMP residues [6,7,46], highly-conserved and highly-vari-
able TM2 positions segregated to opposite sides of a helical wheel
(Fig. 1b), with the former transcribing a contiguous surface
(Fig. 1c). We also noted that the ﬁve highly-conserved TM2 residues
were predicted to be protein-facing [36]. Co-localization of highly-
conserved TM2 residues at a contiguous, protein-facing surface
strongly implied that at least one of these residues contributed to
EmrE stability and/or activity. To evaluate this contention, we indi-
viduallymutated theﬁvehighly-conservedEmrE residues, aswell as
two semi-conserved and two semi-variable residues that border the
highly-conservedpositions (Fig. 1c). Substitutionsweredesigned to:
(i) alter side chain volume to disrupt protein–protein and/or pro-
tein–substrate contacts [47]; and (ii) maintain TM2 hydrophobicity
to minimize any potential membrane integration defects [48].
Selected replacement residues, to the best of our knowledge, have
not previously been introduced to EmrE TM2 at corresponding sites
(e.g., [30,36,39,40]). The resulting nine point mutants (T36A, Y40A,
S43L, F44A, W45A, L46A, L47A, A48L, and A52L) andWT EmrE were
examined for their protein accumulation levels in E. coli and for their
ability to sustain E. coli growth in Et-containing media.
3.2. Highly-conserved TM2 residues are required for EmrE activity, but
not always for protein accumulation
Alteration of Et resistance among bacteria expressing mutant
vs. WT EmrE may arise from: reduced protein production within
the cell via mRNA stability changes; altered protein insertion, fold-
ing/stability, structure, and/or oligomerization efﬁciency; and/or
from modiﬁed transport activity. We surmised that protein pro-
duction, insertion, and stability changes would predominate in lev-
els of in vivo protein accumulation [39], whereas transporter
oligomerization and/or activity alterations would be reﬂected in
growth rates in Et-containing media [36] corrected for protein
accumulation levels (termed normalized relative growth). Thus,
we consider protein accumulation levels as a surrogate for
in vivo production, insertion, and folding/stability of EmrE TM2
mutants, and normalized growth as directly proportional to the
ability of each mutant transporter to oligomerize and confer resis-
tance to Et in vivo, herein referred to as activity.
Relative protein accumulation levels among WT and TM2 point
mutants were variable (Fig. 2a and b), and trended only very
Fig. 1. TM2 sequence conservation among SMPs. (a) The sequence of EmrE TM2 (residues 34–52) is shown with values of Shannon entropy (H) calculated herein at
corresponding alignment positions (Supplementary ﬁle 1). TM2 positions were sorted by H values into highly-conserved (red), semi-conserved (orange), semi-variable
(yellow), or highly-variable (light yellow) groups (Section 2). (b) Alpha-helical wheel and (c) a-helix surface projection of the EmrE TM2 sequence. Residues are shaded
according to the scheme in (a). Note that highly-conserved and highly-variable residues segregate to opposite surfaces of the helical wheel (b), and that the former deﬁne a
contiguous helix surface [(c), blue ellipse]. Residues where point mutations were constructed in full-length EmrE in this work are boxed in panel (c).
Fig. 2. In vivo protein accumulation and activity of TM2-substituted EmrE. Shown are (a) representative Western blot; (b) relative protein accumulation; and, (c) relative
normalized growth in Et of WT EmrE and its TM2 variants. Bars shown in (b) and (c) represent the mean ± S.E. of 3–8 and 3–4 independent replicates, respectively. Mean
values (indicated above each bar) were used to classify mutants as low, moderate, or as WT (Section 2). Note that Western blot band intensities were corrected for total
transferred protein prior to calculation of relative protein accumulation. In vivo protein accumulation among the group of WT and TM2 mutant EmrE proteins was
statistically distinguishable (P = 0.0020); S43L had an individual accumulation statistically distinguishable from WT (⁄P < 0.05). Relative normalized growth among bacteria
expressing WT or TM2 mutant EmrE proteins was statistically distinguishable (P = 0.0003), with each highly-conserved residue replacement (Y40A, S43L, F44A, L47A, and
A48L) individually statistically distinguishable from WT (⁄⁄P < 0.01; ⁄P < 0.05).
J. Wang et al. / FEBS Letters 588 (2014) 3720–3725 3723generally with conservation group. For example, in vivo accumula-
tion of semi-variable (T36A, L46A) or semi-conserved (W45A, A52L)
site mutants was as WT (110–130% or 80–110%, respectively,
Fig. 2a and b), yet highly-conserved residue replacements had low
(S43L, 10%), moderate (Y40A, F44A, 60%), or as WT (L47A,
A48L,80–110%) protein accumulation (Fig. 2b). S43L was the only
mutant with individual accumulation statistically distinguishable
fromWT (Fig. 2b), and group comparisons indicated only a general
tendency towards low protein accumulation as conservation level
increased (Fig. S1a). Replacement of highly-conserved TM2 sites
thus did not universally result in reduced accumulation of EmrE.
High conservation within TM2 instead reﬂects selection for
in vivo activity. For example, each individual highly-conserved sitereplacement had statistically distinguishable low Et resistance
(625% WT levels of normalized growth, Y40A, S43L, F44A, L47A,
A48L; Fig. 2c). Further, in vivo activity among the group of mutants
at highly-conserved sites was statistically distinguishable from the
groups of semi-conserved and semi-variable site mutants, with
activity reduced by 5-fold among the former vs. the latter two
(Fig. S1b). However, activity among replacements at semi-con-
served and semi-variable sites did not segregate exclusively with
individual residue conservation levels. For example, Et resistance
of the W45A semi-conserved site mutant was as WT, whereas
the semi-variable site replacement T36A had moderate activity
(85% and 45%, respectively, Fig. 2c). Thus, high conservation
in TM2 delineates residues where substitutions are most
3724 J. Wang et al. / FEBS Letters 588 (2014) 3720–3725disruptive to activity, yet variability does not necessarily exclude a
given residue from some role in modulating Et resistance.
4. Discussion
The ﬁve TM2 residues classiﬁed as highly-conserved using
TM2-speciﬁc H values (Tyr40, Ser43, Phe44, Leu47, and Ala48)
are sites where our replacements reduce EmrE Et resistance activ-
ity to <25% of WT levels. However, if H values of complete EmrE are
used to deﬁne residue conservation levels, two of these (Ser43 and
Ala48) are excluded from the highly-conserved group (Table S1).
The TM2-speciﬁc high conservation threshold thus more accu-
rately delineates residues important for activity. Higher residue
diversity within TM2 – relative to other secondary structural ele-
ments among SMPs – appears to underlie this observation. Indeed,
of the nine conserved residues speciﬁc to SMPs [6], three are found
in TM1, two in TM3, three in TM4, one in loop regions, yet zero
localize to TM2. Further, among all SMRs, conservation levels are
highest in TM1 and high in TM4 [6].
Increased variability of highly-conserved residues in TM2, rela-
tive to other SMP sites, implies that at least one of Tyr40, Ser43,
Phe44, Leu47, and/or Ala48 should be more tolerant to substitution
than highly-conserved sites in TMs 1, 3, or 4 (Table 1). The Y40A,
S43L, F44A, L47A, and A48L variants studied in the present work
– like Trp replacements of the same residues [36] – were speciﬁ-
cally selected to perturb TM2 contacts, and we observed that each
series respectively reduces in vivo Et resistance to <25% or <30% of
WT levels. However, alternate substitutions previously reported at
these sites do not universally eliminate EmrE activity, but instead
modify speciﬁcity. For example, Y40C, F, L, M, S, T, and V replace-
ments impaired bacterial growth in Et and Ac but not in MV [40].
Further, S43C, L47C and A48C mutants were essentially unchanged
in resistance to Et and Ac, yet were as WT, moderately impaired, or
unable to confer MV resistance, respectively [39]. Conversely, at
highly-conserved TM1, TM3, and TM4 positions, even subtle
replacements that preserve side chain characteristics inactivate
or severely reduce EmrE-mediated resistance to Et, Ac, and MV
(E14D, Y60F and W63F, and G97A, respectively [21,34,49]). The
spectrum of activity observed among various replacements at
highly-conserved TM2 sites – relative to disruption of pan-resis-
tance among even subtle side chain changes at highly-conserved
residues in TMs 1, 3, and 4 – is consistent with a role for enhanced
residue diversity within TM2 in transporter polyspeciﬁcity. Highly-
conserved TM2 residues are nevertheless important for EmrE activ-
ity, and we conclude that the contiguous surface deﬁned by these
represents a site sensitive to disruption.
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